Fibroid uterus can be managed medically, surgically, or through non-extirpative procedures, depending on the clinical situation. Myomectomy may be beneficial, especially to those desiring to preserve...
To determine the microarchitecture of the cervix using high-resolution diffusion tensor (DT) magnetic resonance imaging (MRI).
Gonadotropin-releasing hormone (GnRH) agonist therapy is used before myomectomy to decrease the size of the fibroids, but its association with fibroid recurrence postoperatively remains unsettled.
From the 9th to the 11th November, Dubai (UAE) will be the home of the 3rd International Paediatric Medical Congress.
Gedeon Richter announced results of PEARL IV, a Phase III, randomized, double-blind, parallel group study investigating the efficacy and safety of...
Pooled analysis from the TOMORROW and INPULSIS trials, recently published in Respiratory Medicine, confirmed that Ofev or Vargatef (nintedanib), from...
Objective: To evaluate the efficacy and adverse events of fezolinetant for treating vasomotor symptoms (VMS) of menopause.
Moderna announced a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA) for an additional commitment of up to $472 million to support late stage clinical development.
Background and purpose: The Phase II TOMORROW trial and two Phase III INPULSIS(®) trials investigated the efficacy and safety of nintedanib versus placebo in patients with idiopathic pulmonary fibrosis (IPF).
Objectives: To determine, in a European cohort, the prevalence and health-related quality-of-life (QOL) burden of moderate-to-severe vasomotor symptoms (VMS) in postmenopausal women, and among subgroups of women not taking hormone therapy (HT).